Bloomberg

• Close: non-farmers are much lower than expected, and fears of raising interest rates have been alleviated.

Us stocks climb to record highsThe unexpectedly weak non-farm payrolls data released last night allayed concerns about rising inflation and a shrinking stimulus package.The dollar plummeted, while Treasury yields barely changed.

The long-awaited non-farm payrolls figures are disturbing, with payrolls rising by just 266000 in April, below expectations of an increase of 1 million. Us Treasury Secretary Yellen said the non-farm payrolls report "highlights the long process of economic recovery" and retains expectations of a return to full employment next year.

Wall Street analysts believe weak non-farm data could boost President Joe Biden's new stimulus package and justify the Fed's loose stance.

• Bloomberg chief strategist: the stock market bubble is not serious, the bull market continues

The stock market in the context of the outbreak has experienced an unusual year, with a large number of new individual investors pouring into the stock market and rising volatility, and recently, technology stocks have sold off after months of sharp gains. There is a lot of news that the stock market has entered the bubble range.

Although there are many headlines about the market bubble, there is little evidence that listed companies have the fundamentals of irrational exuberance. Compared with the dotcom bubble in the late 1990s, the current stock market is far from that level.

-Gina Martin Adams, chief equity strategist at Bloomberg

Wall Street Journal

• AstraZeneca plans to skip the licensing phase and apply for full approval of the use of COVID-19 vaccine in the United States.

People familiar with the matter said$AZN.US (AstraZeneca) $It may skip applying to the (FDA) of the US Food and Drug Administration for emergency use authorization for COVID-19 's vaccine and instead seek a more time-consuming license for full use. The move will further delay the use of the AstraZeneca vaccine in the US, but US government and public health officials say they may not need the AstraZeneca vaccine because Pfizer, Moderna and Johnson vaccines have been urgently licensed and have sufficient stocks.

• Grab's listing of SPAC at US $40 billion may start the listing craze of Southeast Asian technology companies.

Malaysian bus and takeout delivery service providersGrab plans to go public in the United States at SPAC at a valuation of $40 billion, and the deal is expected to close in July. This transaction is the largest SPAC transaction ever.Chua Kee Lock, CEO of, Vertex Holdings, believes that the deal will further attract a large number of investors' attention and interest in Southeast Asian markets.

In recent years, Southeast Asian markets have attracted more and more venture capital. Private equity data provider Preqin data showsLast year, investors made more than 500 investments in start-ups in Southeast Asia, totaling $7.6 billion, a qualitative leap from 65 investments totaling about $200m in 2011.

CNBC

• The goddess ARK is not worried about the pullback of technology stocks and plans to increase her position at every bargain.

ETF, known as Cathie Wood, the goddess of ARK, has pulled back more than 30 per cent from its February peak as the market sold off technology stocks.

The pullback in technology stocks is not a cause for concern, and our long-term investment will pay off over time.Judging from our five-year time span, excellent companies have not changed anything but price, which gives us a chance to make a bottom.。We had expected the investment strategy to generate an annualized return of 15%, but after the recent bottom, we expect that number to rise to between 25% and 30%.

-Cathie Wood, founder of ARK Invest, said in an interview with CNBC

ETF, owned by Ark, had a net outflow of about $760 million last week amid recent weakness in technology stocks, according to FactSet.

• Pfizer CEO opposes US abandonment of COVID-19 Vaccine Patent

$Pfizer (PFE.US) $U.S. president Joe Biden's proposal to give up COVID-19 's patent for vaccine will trigger global competition for raw materials, threatening the safety and efficient production of COVID-19 's vaccine, CEO Albert Bourla warned on Friday.

At present, infrastructure is not the bottleneck of our vaccine production. The real bottleneck is the lack of highly specialized raw materials for vaccine production.Pfizer's vaccine requires 280 different materials and ingredients from 19 countries around the world. Without patent protection, companies that are far less experienced in making vaccines than Pfizer will start competing for raw materials and ingredients.

-Pfizer CEO Albert Bourla

Financial Times

• Goldman Sachs resumes cryptocurrency business to execute its first derivative transaction

Friday,$Goldman Sachs (GS.US) $Executed the bank's first cryptocurrency transaction and set up a bitcoin service business. Rajesh Venkataramani, the head of Goldman's main currency, told employees that two types of bitcoin-related derivatives had been "successfully executed".

Goldman Sachs said on March 1 that it would restart its suspended cryptocurrency business because of growing demand from institutional clients. Goldman was one of the first banks to open an encryption business, but it was set up in 2018 at a time when the price of bitcoin plummeted, prompting Goldman to quietly abandon the original project.

Mathew McDermott, head of the digital assets team, said the restored Goldman trading division would not trade cash encrypted currencies, but futures and non-deliverable forwards.

It is worth pointing out,More and more Wall Street banks are considering providing cryptocurrency investment services.Itay Tuchman, Citi's global head of foreign exchange, reported a surge in customer interest in cryptocurrencies. Citi has not yet determined what services it will provide, and deals, trusteeship and financing are all under consideration.

• Strong investor demand, US corporate debt spreads fell to a three-year low

The risk premium on investment grade bonds narrowed by one basis point to 87 basis points, according to the Bloomberg Barclays index. This level has occurred only a few times since the 2008 financial crisis.

Under the loose policy, the scale of corporate bond issuance is also expanding, but this is still unable to meet the needs of investors. With strong corporate earnings and faster economic expectations and vaccine launches, bond investors are once again scrambling for new investment opportunities, pushing spreads on investment-grade US corporate bonds to a more than three-year low on Friday.

Investors pumped $3.85 billion into corporate bond funds this year, according to Refinitiv, in the week ended May 5.

The above is the headline breakfast of today's foreign media. We sincerely invite you to enjoy it and enjoy your investment.